We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

62 hedge funds and large institutions have $527M invested in Acceleron Pharma in 2013 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,397% more capital invested

Capital invested by funds: $11.7M → $527M (+$515M)

1,350% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 4

675% more funds holding

Funds holding: 8 → 62 (+54)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

Holders
62
Holders Change
+54
Holders Change %
+675%
% of All Funds
1.8%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.09%
New
58
Increased
2
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$51.1M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$43.5M
3
DVC
Deer VII & Co
New York
+$26.7M
4
JP Morgan Chase
JP Morgan Chase
New York
+$18.5M
5
Franklin Resources
Franklin Resources
California
+$14.4M

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.56M
2
ICAP
Independence Capital Asset Partners
Colorado
-$835K
3
MCM
Mazama Capital Management
Oregon
-$445K
4
FSA
Franklin Street Advisors
North Carolina
-$43.4K
5
SSG
Summit Securities Group
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
PVMCI
1
Polaris Venture Management Co IV
Massachusetts
$124M +$75.6M +3,133,234 New
O
2
OrbiMed
New York
$83.9M +$51.1M +2,117,648 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$71.4M +$43.5M +1,803,400 New
DVC
4
Deer VII & Co
New York
$39.4M +$26.7M +1,105,964 New
JP Morgan Chase
5
JP Morgan Chase
New York
$30.3M +$18.5M +766,080 New
Franklin Resources
6
Franklin Resources
California
$23.6M +$14.4M +596,577 New
QF
7
QVT Financial
New York
$21.6M +$13.4M +556,574 New
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$20.8M +$12.7M +525,000 New
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$19.2M +$11.7M +485,800 New
BA
10
BlackRock Advisors
Delaware
$8.28M +$5.05M +209,146 New
DCM
11
Driehaus Capital Management
Illinois
$7.81M +$43.9K +1,817 +0.9%
BFA
12
BlackRock Fund Advisors
California
$6.93M +$4.22M +174,954 New
BIT
13
BlackRock Institutional Trust
California
$6.35M +$3.87M +160,336 New
VOYA Investment Management
14
VOYA Investment Management
Georgia
$5.67M +$3.45M +143,066 New
Vanguard Group
15
Vanguard Group
Pennsylvania
$5.27M +$3.21M +133,176 New
Invesco
16
Invesco
Georgia
$3.96M – – –
Lord, Abbett & Co
17
Lord, Abbett & Co
New Jersey
$3.93M +$2.39M +99,200 New
WSA
18
Wall Street Associates
California
$3.71M +$152K +6,300 +7%
State Street
19
State Street
Massachusetts
$3.59M +$2.18M +90,511 New
Northern Trust
20
Northern Trust
Illinois
$3.46M +$2.11M +87,322 New
FCMI
21
Foresite Capital Management I
California
$2.61M +$1.59M +66,000 New
UBS AM
22
UBS AM
Illinois
$2.58M +$1.57M +65,100 New
Wellington Management Group
23
Wellington Management Group
Massachusetts
$2.23M +$1.36M +56,450 New
Jennison Associates
24
Jennison Associates
New York
$2.19M +$1.34M +55,366 New
SFM
25
Sphera Funds Management
Israel
$1.98M +$1.21M +50,000 New
1
2 3

XLRN Hedge Fund Activity: Q4 2013 in Review

62 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2013, worth a combined $527M — up 4,397% from $11.7M a quarter earlier.

Buyers outnumbered sellers: 58 funds opened new XLRN positions and 4 closed out — a net gain of 54 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $51.1M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.56M sold.

  • 62 institutional investors held Acceleron Pharma (XLRN) as of Q4 2013, up from 8 in Q3 2013.
  • Funds reported $527M of Acceleron Pharma stock for Q4 2013, up 4,397% quarter-over-quarter.
  • 58 funds opened new Acceleron Pharma positions in Q4 2013 and 4 closed out, a net change of +54 holders.
  • The largest Acceleron Pharma buyer in Q4 2013 was OrbiMed, an estimated $51.1M added.
  • The largest Acceleron Pharma seller in Q4 2013 was Alyeska Investment Group, an estimated $1.56M sold.

Based on aggregated 13F filings for Q4 2013.